Edwards Lifesciences CORP Form 4 insider transactions
NYSE
Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports stock transactions including the vesting of performance rights and associated tax withholding.
NYSE
Daveen Chopra, CVP at Edwards Lifesciences, reports the vesting and subsequent disposal of shares related to performance-based restricted stock units.
NYSE
Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised performance rights and sold shares to cover tax obligations.
NYSE
Director Michael Mussallem exercised stock options and sold shares of Edwards Lifesciences Corp. under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Jean-Luc M. Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Form 4: Edwards Lifesciences CFO Scott Ullem Executes Stock Option and Sells Shares Under 10b5-1 Plan
Scott Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NYSE
Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports stock transactions including option exercises and sales under a pre-arranged 10b5-1 trading plan.
NYSE
Jean-Luc M. Lemercier, a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
NYSE
Director Michael Mussallem exercised stock options and sold shares of Edwards Lifesciences (EW) on April 4, 2024, according to a Form 4 filing with the SEC.
NYSE
CVP, Chief Financial Officer Scott B. Ullem reports transactions involving Edwards Lifesciences Corp stock, including option exercises and sales, pursuant to a pre-arranged trading plan.
NYSE
Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NYSE
Jean-Luc M. Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NYSE
Daniel J. Lippis, a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NYSE
Michael Mussallem, a director at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NYSE
Scott Ullem, CFO of Edwards Lifesciences, executed a stock option exercise and subsequent sale of shares under a pre-arranged Rule 10b5-1 trading plan.